Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma

Abstract

This secondary analysis reports the survival outcome in patients with EGFR variant-positive non–small-cell lung cancer who had a body mass index that was higher or lower than 24.